Evidence map›Paper›PMID 40733067›Full record

ReviewPharmaceutics2025

Application of Gene Therapy to Oral Diseases.

Seiichi Yamano, Kenji Inoue, Yoichiro Taguchi

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Seiichi YamanoDepartment of Prosthodontics, New York University College of Dentistry, New York, NY 10010, USA.
Kenji InoueDepartment of Prosthodontics, New York University College of Dentistry, New York, NY 10010, USA.ORCID 0000-0003-3946-9538
Yoichiro TaguchiDepartment of Operative Dentistry, Endodontology and Periodontology, Matsumoto Dental University, Shiojiri-shi 399-0704, Nagano, Japan.

Funding

Intratumor co-delivery of DNA and RNA to relieve cancer painR01DE029694 · NIDCR · NEW YORK UNIVERSITY · PI SCHMIDT, BRIAN L, YAMANO, SEIICHI · 2021 to 2025
$2.9M
Non-viral gene therapy for cancer painR01DE025393 · NIDCR · NEW YORK UNIVERSITY · PI SCHMIDT, BRIAN L, YAMANO, SEIICHI · 2016 to 2018
$1.3M
Non-viral gene therapy for cancer pain.R56DE025393 · NIDCR · NEW YORK UNIVERSITY · PI SCHMIDT, BRIAN L, YAMANO, SEIICHI · 2015 to 2015
$396k
NIH/NIDCR R01DE025393NIH/NIDCR R01DE029694NIH/NIDCR R56DE025393
6 · The paper itself

Abstract

Gene therapy has emerged as a promising therapeutic approach across various oral diseases. This review examines current applications and future prospects of gene therapy in dentistry, focusing on five key areas: oral cancer, cancer-related pain, xerostomia (dry mouth), dental caries, and periodontal disease. Recent advances in viral and non-viral vectors have enabled more efficient gene delivery systems, with particular success in cancer pain management through µ-opioid receptor gene transfer and xerostomia treatment using aquaporin-1 gene therapy. For periodontal applications, gene therapy strategies include both immunomodulation and tissue regeneration approaches using growth factors like platelet-derived growth factor and bone morphogenetic proteins. While significant progress has been made, particularly in treating radiation-induced xerostomia and oral cancer pain, challenges remain in vector optimization and delivery methods. Clinical trials, predominantly in Phase I, indicate both the potential and current limitations of gene therapy in oral healthcare. This review synthesizes current evidence and outlines future directions for gene therapy applications in oral medicine and dentistry.

Indexed as

gene deliverygene therapyoral cancerpain managementperiodontal diseasexerostomia

Identifiers

PMID40733067
PMCPMC12298272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.